Prostate Cancer
Research


Volume 7 Number 11
November 2019


Home > Disciplines > Publications > Prostate Cancer Research > Volume 7, Year 2019 > Number 11, November



CONTENTS


DIAGNOSIS
ETIOLOGY, PATHOGENESIS, PATHOLOGY
FOLLOW-UP, SIDE EFFECTS, QUALITY OF LIFE
INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS
TREATMENT



DIAGNOSIS


Andriole GL.
What is the best PET target for early biochemical recurrence of prostate cancer?
Lancet Oncol. 2019 Nov 1;20(11):e608. doi: 10.1016/S1470-2045(19)30586-8.
Source . Similar articles
Refers to: Calais J, et al., 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Source . Similar articles




Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J.
What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply.
Lancet Oncol. 2019 Nov 1;20(11):e609-e610. doi: 10.1016/S1470-2045(19)30654-0.
Source . Similar articles
Refers to Andriole GL, What is the best PET target for early biochemical recurrence of prostate cancer?
Lancet Oncol. 2019 Nov 1;20(11):e608. doi: 10.1016/S1470-2045(19)30586-8.
Source . Similar articles




England T, Li J, Cohen RJ.
Fifteen-year analysis of prostate biopsies in Western Australia including recent impact of multiparametric magnetic resonance imaging.
ANZ J Surg. 2019 Dec;89(12):1605-1609. doi: 10.1111/ans.15566. Epub 2019 Nov 25.
Source . Similar articles




Kulkarni SC, Sundaram PS, Padma S.
In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen PET computed tomography?
Nucl Med Commun. 2019 Nov 7. doi: 10.1097/MNM.0000000000001110. [Epub ahead of print]
Source . Similar articles




Turkbey B, Choyke PL.
18F-fluciclovine PET or PSMA PET for prostate cancer imaging?
Nat Rev Urol. 2020 Jan;17(1):9-10. doi: 10.1038/s41585-019-0255-6.
Source . Similar articles
Refers to: Calais J, et al., 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Source . Similar articles



ETIOLOGY, PATHOGENESIS, PATHOLOGY


Zhu M, Yu X, Zheng Z, Huang J, Yang X, Shi H.
Capsaicin suppressed activity of prostate cancer stem cells by inhibition of Wnt/β-catenin pathway.
Phytother Res. 2019 Nov 28. doi: 10.1002/ptr.6563. [Epub ahead of print]
Source . Similar articles



FOLLOW-UP, SIDE EFFECTS, QUALITY OF LIFE


Rombouts AJM, Hugen N, Elferink MAG, Poortmans PMP, Nagtegaal ID, de Wilt JHW.
Increased risk for second primary rectal cancer after pelvic radiation therapy.
Eur J Cancer. 2020 Jan;124:142-151. doi: 10.1016/j.ejca.2019.10.022. Epub 2019 Nov 22.
Source . Similar articles



INTEGRATIVE MEDICINE


Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA.
Statin use is associated with lower risk of PTEN-null and lethal prostate cancer.
Clin Cancer Res. 2019 Nov 21. doi: 10.1158/1078-0432.CCR-19-2853. [Epub ahead of print]
Source . Similar articles



OVERALL MANAGEMENT


Ganau M, Gallinaro P, Cebula H, Scibilia A, Todeschi J, Gubian A, Nannavecchia B, Signorelli F, Pop R, Coca HA, Proust F, Chibbaro S.
Intracranial Metastases from Prostate Carcinoma: Classification, Management, and Prognostication.
World Neurosurg. 2019 Oct 31. doi: 10.1016/j.wneu.2019.10.125. [Epub ahead of print]
Source . Similar articles



PROGNOSIS


Bernard B, Burnett C, Sweeney CJ, Rider JR, Sridhar SS.
Impact of age at diagnosis of de novo metastatic prostate cancer on survival.
Cancer. 2019 Nov 26. doi: 10.1002/cncr.32630. [Epub ahead of print]
Source . Similar articles




Caffo O, Wissing M, Bianchini D, Bergman A, Thomsen FB, Schmid S, Yu EY, Bournakis E, Sella A, Zagonel V, De Giorgi U, Tucci M, Gelderblom H, Galli L, Pappagallo G, Bria E, Sperduti I, Oudard S; CASTOR study investigators.
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
Clin Genitourin Cancer. 2019 Sep 27. doi: 10.1016/j.clgc.2019.09.010. [Epub ahead of print]
Source . Similar articles




Frankcombe DE, Li J, Cohen RJ.
Redefining the Concept of Clinically Insignificant Prostate Cancer.
Urology. 2019 Nov 9. doi: 10.1016/j.urology.2019.10.019. [Epub ahead of print]
Source . Similar articles




Leong JY, Herrera-Caceres JO, Goldberg H, Tham E, Teplitsky S, Gomella LG, Trabulsi EJ, Lallas CD, Fleshner NE, Tilki D, Chandrasekar T.
Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis.
Urology. 2019 Nov 6. doi: 10.1016/j.urology.2019.10.012. [Epub ahead of print]
Source . Similar articles



TREATMENT


De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL, Ponti E, Marvaso G, Goetghebeur E, Ost P.
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
Eur Urol. 2019 Dec;76(6):732-739. doi: 10.1016/j.eururo.2019.07.009. Epub 2019 Jul 20.
Source . Similar articles




Goy BW, Burchette R, Soper MS, Chang T, Cosmatos HA.
Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer.
Urology. 2019 Nov 5. doi: 10.1016/j.urology.2019.09.040. [Epub ahead of print]
Source . Similar articles




Jethwa KR, Hellekson CD, Evans JD, Harmsen WS, Wilhite TJ, Whitaker TJ, Park SS, Choo CR, Stish BJ, Olivier KR, Haloi R, Lowe VJ, Welch BT, Quevedo JF, Mynderse LA, Karnes RJ, Kwon ED, Davis BJ.
11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities.
Adv Radiat Oncol. 2019 Jul 4;4(4):659-667. doi: 10.1016/j.adro.2019.06.006.
Source . Similar articles




Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN.
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11.
Source . Similar articles




Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M, Bryant R, Bollina P, Catto J, Doherty A, Gillatt D, Gnanapragasam V, Holding P, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Altman DG, Hamdy FC; ProtecT Study Group.
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
Eur Urol. 2019 Nov 24. doi: 10.1016/j.eururo.2019.10.030. [Epub ahead of print]
Source . Similar articles




Park J, Yoo S, Cho MC, Jeong CW, Ku JH, Kwak C, Kim HH, Jeong H.
Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance.
Urol Int. 2019 Nov 6:1-6. doi: 10.1159/000503888. [Epub ahead of print]
Source . Similar articles




Valeriani M, Marinelli L, Macrini S, Reverberi C, Aschelter AM, De Sanctis V, Marchetti P, Tronnolone L, Osti MF.
Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.
Radiat Oncol. 2019 Nov 14;14(1):205. doi: 10.1186/s13014-019-1414-x.
Source . Similar articles




Yoshida K, Takahashi N, Karnes RJ, Froemming AT.
Prostatic Remnant After Prostatectomy: MR Findings and Prevalence in Clinical Practice.
AJR Am J Roentgenol. 2020 Jan;214(1):W37-W43. doi: 10.2214/AJR.19.21345. Epub 2019 Oct 31.
Source . Similar articles



bottom